Abstract: A 1,4-dihydropyridine derivative having the formula (I): ##STR1## wherein X is oxygen atom or nitrogen atom; when X is oxygen atom, R.sup.1 is hydrogen atom, a lower alkyl group, a lower cycloalkyl group, a lower alkenyl group or magnesium atom, when X is nitrogen atom, X-R.sup.1 group is NH.sub.2, NHR.sup.1', NR.sup.1' R.sup.1" or ##STR2## in which R.sup.1' is a lower alkyl group or a lower alkoxyalkyl group, R.sup.1" is a lower alkyl group and n is an integer of 2 to 6; R.sup.2 is a lower alkyl group, a lower cycloalkyl group or a lower alkoxyalkyl group and R.sup.3 is a lower alkyl group, formyl group, dimethoxymethyl group, cyano group or amino group, when X is oxygen atom and R.sup.1 is hydrogen atom or magnesium atom, R.sup.3 is methyl group, when X is nitrogen atom, R.sup.3 is methyl group, or a pharmaceutically acceptable salt thereof, some processes for preparing the same and a pharmaceutical composition containing the same.

Abstract: A composition for producing a metallic sintered body consisting essentially of a mixture of a powdered metal having an average particle size of not more than 50 microns with a lactone resin having a relative viscosity value in the range of from 1.15 to 3.20 is disclosed.The composition has excellent properties such as mechanical strength of a green body thereof, and only a short time being necessary for removal or elimination of binder in comparison with conventional sintering compositions.Furthermore, the binder in the present composition is substantially composed of a single component; accordingly, manufacturing process control can be simplified by use of the lactone resin.Furthermore, a method for producing a metallic sintered body using such composition is also disclosed.

Abstract: A composition for producing a metallic sintered body consisting essentially of a mixture of a powered metal having an average particle size of not more than 50 microns with a lactone resin having a relative viscosity value in the range of from 1.15 to 3.20 is disclosed.The composition has excellent properties such as mechanical strength of a green body thereof, and only a short time being necessary for removal or elimination of binder in comparison with conventional sintering compositions.Furthermore, the binder in the present composition is substantially composed of a single component; accordingly, manufacturing process control can be simplified by use of the lactone resin.Furthermore, a method for producing a metallic sintered body using such composition is also disclosed.

Abstract: Polyester-polysiloxane block copolymers for dental uses are disclosed as low modulus thermoplastic elastomers. The copolymers comprise polycaprolactone residues and poly(dimethylsiloxane) .alpha.,.omega.-diol residues which are linked by ether bonds. The compounds exhibit the property of plasticity by heating and the property of original rubber elasticity by cooling again to room temperature.

Abstract: A synthetic resin composition comprises (A) 100 parts by weight of polycaprolactone and (B-1) 10 to 70 parts by weight of a thermoplastic resin and 1 to 30 parts by weight of a tackifier, or (B-2) 10 to 70 parts by weight of a chlorinated polyolefin.

Abstract: New thermoplastic polyester resins having a low melting point which are useful as a molding material, especially as an orthopedic cast material; said resin having the formula (I):[A].sub.1 [B].sub.m [C].sub.n (I)where A denotes a residue of a straight or branched aliphatic dicarboxylic acid having 4 to 12 or 36 carbon atoms; B denotes a residue of a straight or branched aliphatic diol having 2 to 18 carbon atoms; C denotes a residue of 6-hydroxycaproic acid; these residues are linked through the ester bond and distributed randomly and/or in block in the molecule; 1, m, and n each has a value greater than 0; the residue of the 6-hydroxycaproic acid is 60 to 98 wt % and the sum of the residues of the aliphatic dicarboxylic acid and aliphatic diol is 40 to 2 wt %; the residue of the aliphatic dicarboxylic acid and the residue of the aliphatic diol are present in equimolar amount; and having a number-average molecular weight of 5,000 to 200,000.

Abstract: In a process for producing a lactone polyester which comprises ring-opening polymerization of a lactone in the presence of a metal containing organic compound as a catalyst, the improvement wherein said compound is an alcoholate, chelate or organic acid salt of vanadium or molybdenum.

Abstract: A process for preparing a water-soluble alkyd resin, which comprises(1) reacting(i) at least one of(a) a 1,2-epoxyalkane containing 6 to 28 carbon atoms,(b) a straight-chain internal epoxyalkane containing 6 to 20 carbon atoms,(c) a mixture of one or more of the 1,2-epoxyalkane (a) and/or the internal epoxyalkane (b), or(d) a mixture of one or more of the 1,2-epoxyalkane (a) and/or the internal epoxyalkane (b) and an unsaturated fatty acid containing 12 to 18 carbon atoms in a molar ratio of about 4:1 to about 2:1 of the 1,2-epoxyalkane (a) and/or the internal epoxyalkane (b) to the unsaturated fatty acid;with(ii) at least one of(a') an aromatic carboxyl compound selected from the group consisting essentially of phthalic anhydride, isophthalic acid, terephthalic acid, an ester of isophthalic acid and an ester of terephthalic acid,(b') a mixture of two or more of the aromatic carboxyl compounds (a'), or(c') a mixture of one or more of the aromatic carboxylic compounds (a') and an aliphatic dicarboxylic acid ha

Abstract: Pharmaceutical compositions containing 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride and a method of using such compositions in treatment of liver dysfunction in mammals are disclosed.

Abstract: Thienodiazepines of the formula: ##STR1## wherein Ar is mono- or di-substituted phenyl [the substituents(s) being H, halogen, C.sub.1.sub.-4 alkyl or C.sub.1.sub.-4 alkoxy] or pyridyl; R.sup.1 is H or C.sub.1.sub.-4 alkyl; R.sup.2 is H, halogen or C.sub.1.sub.-4 alkyl; or R.sup.1 and R.sup.2 combinedly form -(CH.sub.2).sub.4 -; each of R.sup.3 and R.sup.4 is C.sub.1.sub.-4 alkyl, or R.sup.3 and R.sup.4 together with the adjacent nitrogen atom form a heterocyclic group; A is C.sub.2.sub.-4 alkylene; and n is an integer of zero and 1; and pharmaceutically acceptable acid addition salts thereof are disclosed. They are useful as analgesics.

Abstract: Substituted phenylalkanoic acids and derivatives thereof of the formula: ##SPC1##Wherein each of R.sup.1 and R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; each of X.sup.1 and X.sup.2 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; Y is COOH, COOR (wherein R is an alkyl group having 1 to 4 carbon atoms), CONH.sub.2, CSNH.sub.2, CN or COZ--A--N(R.sup.3)(R.sup.4) (wherein Z is an oxygen atom or an imino group, A is an alkylene group having 2 to 4 carbon atoms and each of R.sup.3 and R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, or R.sup.3 and R.sup.

Abstract: Compounds of the formula: ##SPC1##WhereinOf X.sup.1 and X.sup.2 is a hydrogen atom, a halogen atom or an alkyl group having 1 to 4 carbon atoms;R.sup.1 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a group -B.sup.1 -R.sup.3 (wherein B.sup.1 is an alkylene group having 1 to 4 carbon atoms, and R.sup.3 is a carboxyl group, an alkoxycarbonyl group in which the alkoxy moiety has 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or a di-alkyl-amino group in which each alkyl moiety has 1 to 4 carbon atoms);R.sup.2 is an alkyl group having 1 to 4 carbon atoms or a group -B.sup.2 -R.sup.4 (wherein B.sup.2 is an alkylene group having 2 to 4 carbon atoms, and R.sup.

Abstract: Triazolothienodiazepine compounds of the formula; ##SPC1##Wherein X is a member selected from the group consisting of a hydrogen atom, a methyl group, a methoxy group and a trifluoromethyl group; each of R.sup.1 and R.sup.2 is a member selected from the group consisting of a hydrogen atom and an alkyl group having 1 to 4 carbon atoms, or R.sup.1 and R.sup.2 together can form a tetramethylene group, i.e.--(CH.sub.2).sub.4 --; R is a member selected from the group consisting of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, --CONHR.sup.3 (R.sup.3 being an alkyl group having 1 to 4 carbon atoms) and -alk-N(R.sup. 4)(R.sup.5) (each of R.sup.4 and R.sup.5 being a member selected from the group consisting of a hydrogen atom and an alkyl group having 1 to 4 carbon atoms, or R.sup.4 and R.sup.

Abstract: Substituted pyrrolidinemethanols of the formula: ##SPC1##Wherein R.sup.1 and R.sup.2 are each H or C.sub.1.sub.-4 alkyl; R.sup.3, R.sup.4 and R.sup.5 are each H, halogen, C.sub.1.sub.-4 alkyl or C.sub.1.sub.-4 alkoxy, or R.sup.3 and R.sup.4 combinedly form methylenedioxy; and R is C.sub.1.sub.-10 alkyl or a group of the formula: ##SPC2##Where R.sup.6, R.sup.7 and R.sup.8 are each H, halogen, C.sub.1.sub.-4 alkyl or C.sub.1.sub.-4 alkoxy, or R.sup.6 and R.sup.7 combinedly form methylenedioxy; and pharmaceutically acceptable acid addition salts thereof are disclosed. They are useful as drugs for the treatment of diseases of the heart and circulation.

Abstract: Substituted alkanoic acids and derivatives thereof of the formula: ##SPC1##Wherein each of X.sup.1 and X.sup.2 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; each of R.sup.1 and R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; A is a carbonyl group, a methylene group or an alkylidene group having 2 to 4 carbon atoms; Y is --O--, --S-- or --N(R)-- [wherein R is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms]; Z is OH or Q--B--N(R.sup.3)(R.sup.4) [wherein Q is O (oxygen atom) or NH, B is an alkylene group having 1 to 4 carbon atoms and each of R.sup.3 and R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, or R.sup.3 and R.sup.

Abstract: Heterocyclic compounds of the formula: ##SPC1##Wherein A is a carbonyl group, a methylene group or an alkylidene group having 2 to 4 carbon atoms; B is an oxygen atom, a sulfur atom or --N(R')-- (wherein R' is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms); each of R.sup.1 and R.sup.2 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or a phenyl group which may be substituted by a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; X is an alkyl group having 1 to 4 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or OM (wherein M is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a metal atom or NH.sub.4); and ring P represents a pyridine ring, are useful as anti-allergic agents.